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Multiplex Ligation-Dependent Probe Amplification of
Uveal Melanoma: Correlation with Metastatic Death
Bertil Damato,1 Justyna Dopierala,2 Annelies Klaasen,3 Marcory van Dijk,4
Julie Sibbring,5 and Sarah E. Coupland2
PURPOSE. To evaluate multiplex ligation-dependent probe am-
plification (MLPA) of uveal melanoma as a predictive tool for
metastatic death.
METHODS. Uveal melanoma specimens of 73 patients treated
between 1998 and 2000 were included. DNA samples were
analyzed with MLPA evaluating 31 loci on chromosomes 1, 3,
6 and 8, and the results were correlated with metastatic death.
RESULTS. The patients (27 women; 46 men) had a median age of
60.6 years and a median follow-up of 6.2 years. Metastatic
death occurred in 28 patients, correlating most strongly with
chromosome 3 losses and gains on 8q (Cox univariate analysis,
P  0.001). Chromosome 6, region p25, gains correlated with
good survival (Cox univariate analysis, P  0.003). Prediction
of metastatic death was improved by considering equivocal
chromosome 3 losses as abnormal and by taking account of
multiple risk factors, such as 8q gains, tumor diameter, and
histologic features indicative of high-grade malignancy.
CONCLUSIONS. MLPA analysis of uveal melanoma predicts meta-
static death if statistically insignificant losses of chromosome 3
are considered together with gains in 8q as well as clinical
stage and histologic grade of malignancy. (Invest Ophthalmol
Vis Sci. 2009;50:3048–3055) DOI:10.1167/iovs.08-3165
Approximately 40% to 50% of uveal melanomas are fatal,usually as a result of metastatic disease, which almost
always involves the liver.1 Estimation of risk of metastatic death
would help reassure patients with a good prognosis while
enabling any screening for metastasis, systemic adjuvant ther-
apy, and other special measures to be targeted at patients with
a poor survival probability.
The main risk factors for metastasis in uveal melanoma
include large basal diameter (LBD) of the tumor, ciliary body
involvement, extraocular spread, epithelioid cellularity, closed
connective tissue loops, high mitotic rate, and certain karyo-
typic abnormalities, particularly those involving chromosomes
1, 3, 6, and 8.2–10
The most important chromosomal abnormality associated
with metastatic death is monosomy 3, which usually involves
the loss of an entire chromosome.6 Gains in chromosome 8
also indicate a poor prognosis and can consist of trisomy 8,
isochromosome 8q, and additions in the C-MYC region.7 Met-
astatic mortality also correlates with 1p loss.10 Conversely, 6p
gains are associated with a good prognosis, these abnormalities
usually being mutually exclusive with monosomy 3.7,9
Since 1999, we have offered cytogenetic analysis to all
patients with uveal melanoma treated by local resection or
enucleation, and we have used fluorescence in situ hybridiza-
tion (FISH) for this purpose. An audit of 356 patients showed
a high correlation between monosomy 3 and metastatic death;
however, in the absence of monosomy 3, the actuarial 5-year
rate of metastatic death ranged from 31% to 6%. depending
respectively on whether or not there were gains in chromo-
some 8.11 We presumed that this was because of partial dele-
tions that were missed by FISH.12,13 To address this problem,
we developed an artificial neural network that estimated sur-
vival prognosis according to age, sex, clinical tumor stage,
histologic grade of malignancy, and presence or absence of
monosomy 3.14 To some extent, this program compensated for
missed chromosome 3 deletions by estimating the likelihood of
these being present, according to the other risk factors
present. Although the artificial neural network alleviated the
problem caused by the low sensitivity of FISH, we decided to
deploy more sensitive methods of genomic typing, which
could be applied in routine clinical practice.
We therefore adopted multiplex ligation-dependent probe
amplification (MLPA), which comprises a set of 43 probes,
each hybridizing to a specific genomic sequence.15 The probes
have different molecular weights and lengths so that after
amplification by polymerase chain reaction (PCR), they can be
separated by gel electrophoresis and quantified in comparison
with control sequences. We used the Salsa P027 (MRC-Holland,
Amsterdam, The Netherlands), a kit specifically designed for
uveal melanoma. The kit comprises 12 control probes and test
probes directed at 7 loci on chromosome 1, 13 on chromo-
some 3, 6 on chromosome 6, and 5 on chromosome 8.
The purpose of this study was to identify the MLPA results that
correlate best with metastatic death from uveal melanoma so that
estimation of the prognosis for survival can be enhanced.
METHODS
Patients
DNA from frozen tumor specimens remaining from a previous study on
uveal melanoma were retrieved from storage.16 The patients had been
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referred to the Liverpool Ocular Oncology Center between January
1998 and February 2000. They underwent full preoperative ophthal-
mic and systemic examinations that included slit lamp and ophthalmo-
scopic examination and echographic measurement of largest and
smallest basal tumor dimensions and tumor thickness. Treatment was
by enucleation or transscleral local resection. As soon as possible after
surgery, a fresh tumor sample was collected for experimental pur-
poses. Part of each tumor was snap frozen in liquid nitrogen, and the
remainder was formalin fixed and embedded in paraffin. Histologic
features were recorded from hematoxylin and eosin and PAS-stained
sections of paraffin-embedded tumors.
Clinical, histologic, and chromosomal data were recorded in a
computerized database. Patients residing in mainland Britain were
flagged in the National Cancer Registry, which automatically informed
us of any deaths, together with the date and cause of death. Follow-up
information on overseas patients was obtained whenever possible by
writing to the referring ophthalmologist or family doctor. The time
until death was calculated from the date of local resection or enucle-
ation.
The research adhered to the tenets of the Declaration of Helsinki.
Informed consent was obtained from the patients after explanation of
the nature and possible consequences of the study. Ethics committee
approval was obtained.
MLPA Technique
DNA extraction, DNA quality assessment and quantification, and MLPA
were performed as previously reported but with an improved protocol
(Dopierala J, et al., unpublished data, 2008).15
DNA Extraction
Briefly, the frozen uveal melanoma samples and control specimens
consisting of normal choroidal tissue were collected in microfuge
tubes. Tissue lysis and protein digestion were performed in a mix of
87% TSE buffer (10 mM Tris/HCl [pH 7.5], 0.4 M NaCl, 2 mM EDTA [pH
8.0]), 0.9% of SDS, and proteinase K (1.64 mg/L; Qiagen GmbH,
Hilden, Germany). Samples were incubated overnight at 56°C (Eppen-
dorf Thermomixer Comfort; Sigma-Aldrich, St. Louis, MO). Fresh pro-
teinase K was added after 16 hours of incubation, and samples were
incubated for an additional 4 hours. Genomic DNA was isolated by
using a high salt concentration (5 M NaCl) and ethanol precipitation.
DNA was dissolved in 20 to 100 L of TE buffer (10 mM Tris [pH 8.5],
1 mM EDTA [pH 8.0]), depending on pellet size.
DNA Quantification and Quality Assessment
DNA concentration and absorbance at 280 and 260 nm were measured
(Nano Drop System; NanoDrop, Minneapolis, MN). FSH-receptor PCR
(forward primer CTA CCC TGC ACA AAG ACA GTG; reverse primer
GTG TAC GTC ATG TCA AAT CCT CTG C) was performed to assess
DNA quality in a thermal cycler (G-Storm GS1; GRI, Ltd., Braintree,
UK), with a DNA polymerase kit (GoTaq Flexi; Promega, Madison WI).
FSH-receptor PCR products were run on stained 2% agarose gel (SYBR
Safe stain; Invitrogen; Groningen, The Netherlands). Electrophoresis
was run at 120 V for 30 minutes, and the results were visualized with
a transilluminator (Benchtop 2UV; Bio Doc-It Imaging System; UVP,
Upland, CA).
MLPA Procedure and Sequencing
An MLPA kit (Salsa P027; MRC-Holland) was used to identify chromo-
somal imbalances in the uveal melanoma samples. The kit consists of
31 probes selected on chromosomes 1 (short arm), 3, 6, and 8, which
often show aberrant copy numbers in uveal melanoma cells, as well as
12 control probes on chromosomes 5, 7, 12, 14, 18, 19, 20, and 21.
Two-hundred nanogram aliquots of DNA extracted from uveal mela-
noma cells as well as four to six normal choroidal tissue control
samples were dissolved in 5 L of TE buffer and transferred to PCR
tubes. TE buffer (5 L) was used as a negative control in each run. The
MLPA reaction was performed in the thermal cycler (G-Storm GS1; GRI
Ltd.). After the MLPA PCR reaction, 4 L of these products were mixed
with loading buffer and were run on a stained 2% agarose gel (SYBR
Safe stain; Invitrogen) to confirm amplification of the ligation products.
After amplification was confirmed, 1 L of MLPA products was mixed
with 8.8 L of highly deionized HI-DI formamide (Applied Biosystems,
Inc. [ABI], Foster City, CA) and 0.2 L of an internal lane size standard
(GeneScan-500 LIZ Size Standard; ABI). Samples were separated by
electrophoresis on a 16-capillary genetic analyzer (model 3130XL,
analyzed by GeneMapper software; ABI) in the Molecular Genetics
Department of the Liverpool Women’s Hospital. Data were received as
peak heights, as a measure of peak intensity, for each of 43 probes for
each sample. Each tumor sample was tested using MLPA at least three
independent times.
Data Analysis
Raw data obtained after sequencing were analyzed in a spreadsheet-
based approach (Excel; Microsoft, Redmond, WA) designed by the
National Genetics Reference Laboratory, Manchester, UK (http://www.
ngrl.org.uk/Manchester/mlpapubs.html). The results from the uveal mel-
anoma samples were compared with a group of five normal choroid tissue
controls, run simultaneously. Data from each test and control sample were
normalized by summing the total control probes’ peak height and by
dividing each ligation product’s peak height by this figure. The control
and test data were then equalized by dividing the normalized peak height
by mean peak height of all five controls. Linear regression was performed
to correct for sloping. Regression coefficients were calculated for each of
five controls and the test samples, according to the probe lengths. Equal-
ized control and test sample’s ligation products were corrected for slop-
ing, and the average results from five control samples for each ligation
product were calculated. The Dosage Quotients (DQs) were calculated by
dividing the test sample matrix by the control mean matrix. The DQ was
categorized as: low, 0.65; equivocally low, 0.65–0.84; normal, 0.85–
1.14; equivocally high, 1.15–1.34; and high, 1.34. The standard devia-
tion of mean DQs of control probes for normal control and test samples
were calculated. Samples were included in this analysis only if the DQs of
the control probes had an SD  0.2 (higher values indicating poor DNA
quality or DNA fragmentation). This amounted to a total of 73 uveal
melanomas; 30 samples were excluded.
Correlations between MLPA results and survival were performed
(ver.11.0; SPSS Science, Chicago, IL), and Kaplan-Meier estimates were
used to draw survival curves for time to metastasis-related death.
Associations between metastasis-related death and risk factors were
assessed with log rank analysis for categorical variables and with Cox
univariate analysis for MLPA DQs.
RESULTS
The 73 patients (46 men and 27 women) had a mean age of
60.6 years (range, 25.2–90.5). The tumors had a mean LBD of
15.0 mm (range, 5.1–21.2), with 31 involving ciliary body (i.e.,
pars plana and/or pars plicata) and 2 extending extraocularly.
Histologic examination showed epithelioid cells in 59 tumors
and closed loops in 51 tumors, with the mitotic rate exceeding
5 per 40 high-power fields in 34 tumors. MLPA showed no
chromosome 3 abnormalities in 31 patients, 1 abnormal locus
in 4 patients, 2 to 9 abnormal loci in 12 patients, and 10 to 13
abnormal loci in 26. The follow-up times had a median of 6.2
years in 35 survivors, exceeding 5 years in 33 patients and 8
years in 31. A total of 38 patients died, the cause of death being
metastatic uveal melanoma in 28, other malignancy in 2, and
other causes in 8 (cardiac failure, 2; myocardial infarction, 2;
cerebrovascular disease, 1; old age, 1; pneumonia, 1; and un-
certain, 1). One patient developed hepatic metastasis after
treatment of a monosomy 3 melanoma and was alive and well
at the close of the study, having undergone a successful partial
hepatectomy.
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Nine patients had FISH analysis of their tumors, which
showed monosomy 3 in four cases and disomy 3 in five. In the
four tumors with monosomy 3 on FISH testing, MLPA showed
unequivocal loss of 12 or 13 chromosome 3 loci in three cases
and equivocal loss of eight loci in one. In the five tumors with
disomy 3 on FISH testing, MLPA showed equivocal loss of one
chromosome 3 locus in two tumors. Eight tumors had FISH
data on chromosome 8. In the three tumors with no chromo-
some 8 gains on FISH testing, MLPA showed equivocal gain of
one locus in one case and unequivocal gains in three loci in
another. FISH indicated chromosome 8 gains in five cases, and
in these MLPA showed unequivocal gains of all four 8q loci in
four tumors and equivocal gains of three adjacent 8q loci in
one. MLPA indicated the 8p locus to be normal in seven tumors
and lost in one case of monosomy 3.
Table 1 shows the correlations between MLPA results and
metastatic death, using Cox univariate analysis. All chromo-
some 3 loci (i.e., losses) and all chromosome 8q loci (i.e.,
gains) correlated strongly with metastatic death. Gains in 6p25
showed a strong inverse correlation with metastasis (i.e.,
strongly indicated a good prognosis). Loss of 8p showed a
borderline correlation with worse prognosis. Figure 1 shows
boxplots of the MLPA results according to survival.
Table 2 shows the results of Cox multivariate analysis in-
cluding 3q12, 8q11.23, and 6p25.2 in the model predicting
metastatic death. Only loci in chromosomes 3 and 8 showed
significant correlations.
Figure 2 shows Kaplan-Meier survival curves according to
whether chromosome 3 loss was considered abnormal if the
MLPA results were equivocal (Fig. 2A) or unequivocal (Fig. 2B).
Figure 2A indicates that (1) when only unequivocal losses of
chromosome 3 loci were considered abnormal, 4 (13%) of 31
patients without such definite abnormalities died of metastatic
disease; and (2) high mortality occurred irrespective of the
number of abnormal chromosome 3 loci. In Figure 2B, when
even equivocal losses of chromosome 3 loci were considered
abnormal, only 1 (4.5%) of 22 patients with normal chromo-
some 3 results died of metastatic disease (this was an unusual
tumor, see Fig. 3A). Mortality was higher if all 13 chromosome
3 loci examined using MLPA showed equivocal loss than if
fewer loci were abnormal. There were 21 patients with equiv-
ocal losses involving only part of chromosome 3, and in these
patients the 10-year survival probability was 60%. In Figure 2C,
tumors were categorized as having no abnormalities in chro-
mosome 3, only equivocal abnormality and definite abnormal-
ity (i.e., unequivocal loss of any locus). Only nine patients
showed a moderate survival prognosis (a result that is clinically
unhelpful). Figure 2D shows survival according to whether
there was loss of any chromosome 3 loci and whether there
was gain in 8q11.23. Such abnormalities were considered sig-
TABLE 1. Cox Univariate Analysis Correlating MLPA Results with Metastatic Death
Probe Locus B SE Wald Sig. Exp(B)
95% CI for Exp(B)
Lower Upper
MFN2 1p36.22 1.017 0.980 1.076 0.300 0.362 0.053 2.470
NBL1 1p36.13 1.379 0.955 2.085 0.149 0.252 0.039 1.637
PTAFR 1p.34 0.606 0.934 0.421 0.517 0.546 0.088 3.402
MYCBP 1p.34 0.194 0.945 0.042 0.838 0.824 0.129 5.255
MUTYH 1p33 0.554 0.910 0.371 0.543 0.575 0.097 3.417
RPE65 1p31 1.457 1.081 1.818 0.178 0.233 0.028 1.937
NOTCH2 1p11.2 2.093 1.172 3.189 0.074 0.123 0.012 1.227
FANCD2(i) 3p25.3 4.042 1.104 13.417 0.001 0.018 0.002 0.153
FANCD2(ii) 3p24.3 2.981 0.877 11.542 0.001 0.051 0.009 0.283
VHL 3p25.3 3.093 0.876 12.474 0.001 0.045 0.008 0.252
MLH11 3p22.1 3.093 0.876 12.474 0.001 0.045 0.008 0.252
CTNNB11 3p22 3.163 0.943 11.246 0.001 0.042 0.007 0.269
SEMA3B 3p21.3 4.105 1.086 14.283 0.001 0.016 0.002 0.139
FHIT(i) 3p14.2 3.250 0.931 12.198 0.001 0.039 0.006 0.240
FHIT(ii) 3p14.2 3.420 0.998 11.738 0.001 0.033 0.005 0.231
ROBO1 3p12.2 3.131 0.868 13.001 0.001 0.044 0.008 0.240
CPO 3q12 4.774 1.175 16.495 0.001 0.008 0.001 0.085
RHO 3q21.3 3.589 0.988 13.186 0.001 0.028 0.004 0.192
MME 3q25.1 4.620 1.210 14.580 0.001 0.010 0.001 0.106
OPA1 3q29 4.594 1.178 15.210 0.001 0.010 0.001 0.102
FOXC1 6p25 1.874 0.692 7.326 0.007 0.153 0.039 0.596
SERPINB9 6p25.2 2.097 0.705 8.850 0.003 0.123 0.031 0.489
CDKN1A 6p21.2 1.497 0.732 4.175 0.041 0.224 0.053 0.941
RUNX2 6p21 1.964 0.868 5.121 0.024 0.140 0.026 0.769
CTGF 6q23.1 0.332 0.858 0.150 0.698 0.717 0.133 3.856
IGF2R 6q26 0.306 0.894 0.117 0.732 0.736 0.128 4.243
NRG1 8p12 1.822 0.883 4.260 0.039 0.162 0.029 0.912
RP1 8q11.23 1.666 0.304 29.932 0.001 5.291 2.913 9.609
MYC(i) 8q24.12 1.415 0.337 17.674 0.001 4.118 2.129 7.966
MYC(ii) 8q24.12 1.330 0.328 16.433 0.001 3.779 1.987 7.188
DDEF1 8q24.2 1.500 0.328 20.861 0.001 4.480 2.354 8.527
MFN2, mitofusin2; NBL1, neuroblastoma, suppressor of tumorigenicity 1; PTAFR, platelet activating factor receptor; MCYBP, c-Myc binding
protein; MUTYH, mutY homolog; RPE65 retinal pigment epithelium specific protein 65; NOTCH2, notch homolog 2; FANCD2, Fanconi anemia
complementation group D2; VHL, von Hippel Lindau; MLH1, MutL homolog 1; CTNNB1, catenin, beta-1; SEMA3B, semaphoring 3B; FHIT, fragile
histidine triad gene; ROBO1, roundabout, axon guidance receptor, homolog 1; CPO, coproporphyrinogen oxidase; RHO, rhodopsin; MME,
membrane metallo-endopeptidase; OPA1, optic atrophy 1; FOXC1, forkhead box Cl; SERPINB9, serpin peptidase inhibitor, clade B, member 9;
CDKN1A, cyclin dependent kinase inhibitor 1A; RUNX2, runt related transcription factor; CTGF, connective tissue growth factor; IGF2R,
insulin-like growth factor 2 receptor; NRG1, neuregulin 1; RP1, retinitis pigmentosa 1; DDEF1, DDEF intronic transcript 1; B, B statistic; Sig.,
significance; Exp, exponent; CI, confidence interval.
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nificant, even if equivocal. None of six patients with no abnor-
malities died of metastasis compared with 80% of patients with
abnormality of both chromosomes.
Figure 3A shows the MLPA results of the above-mentioned
single patient with no chromosome 3 loss (i.e., equivocal or
unequivocal). This patient showed apparent gains in 3p25.3
and 3p22.1 and low normal values of 3p21.3 and 3q21.3 as
well as gains in 8q. Three patients showed equivocal loss of
one or more chromosome 3 loci (Figs. 3B–D). The patient in
Figure 3B showed equivocal loss of all four 3q loci with equiv-
ocal gains in 8q. The patient in Figure 3C showed equivocal
losses of several 3p loci and 3q29 and gains in 8q. Case 3D
showed equivocal losses in 3p22 and 3p14.2 as well as gains in
6p and 8q.
Figure 4 shows survival in patients with lethal melanomas
(i.e., tumors with equivocal or definite abnormality of chromo-
somes 3 and/or 8q). Survival correlated strongly with tumor
diameter (log rank, P  0.002; Fig. 4A) and presence of closed
loops (log rank, P  0.002; Fig. 4C), weakly with the presence
of epithelioid cells (probably because few lethal melanomas
were purely of spindle cell type) (log rank, P  0.024) (Fig.
4B), and nonsignificantly with mitotic rate (log rank, P  0.14;
Fig. 4D).
DISCUSSION
To our knowledge, this is the first study to correlate metastatic
death with MLPA results obtained with the Salsa P027 uveal
melanoma kit (MRC-Holland). We found that several fatal tu-
mors showed only equivocal MLPA abnormalities of chromo-
some 3 loci. Correlation with metastatic disease improved
when we considered other risk factors, such as chromosome 8
gains, basal tumor diameter, and histologic features suggestive
of high-grade malignancy, such as cell type, and closed loops
1p and 6p abnormalities were relatively uninformative.
We selected MLPA to examine the chromosomal abnormal-
ities in uveal melanomas because it provides more information
than FISH, the sensitivity of which has been questioned by us
and others.11,17 MLPA also requires smaller samples than FISH
and can be used on DNA extracted from formalin-fixed, paraf-
fin-embedded tissues.15 Furthermore, it is relatively inexpen-
sive, so that it is affordable for routine clinical use in a large
number of patients. MLPA has been used to investigate uveal
melanomas (deploying an aneuploidy kit, Salsa P095; MRC-
Holland) and cutaneous melanocytic tumors.18,19 We are cur-
rently using MLPA as the first-line investigational procedure for
chromosomal abnormalities in uveal melanomas recently diag-
FIGURE 1. Dosage quotients of each
MLPA probe, according to survival,
with nonfatal and fatal tumors indi-
cated by hatched and gray boxes,
respectively. Dotted lines: separate
normal from equivocal abnormality;
dashed lines: demarcate equivocal
from definite abnormality.
TABLE 2. Cox Multivariate Analysis Correlating MLPA Results with Metastatic Death
Locus B SE Wald Sig. Exp(B)
95% CI for Exp(B)
Lower Upper
3q12 4.085 1.525 7.176 0.007 0.017 0.001 0.334
8q11.23 1.220 0.339 12.980 0.001 3.388 1.745 6.581
6p25.2 0.292 0.833 0.123 0.726 1.339 0.262 6.852
B, B statistic; Sig., significance; Exp, exponent; CI, confidence interval.
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nosed at the Liverpool Ocular Oncology Center and have
analyzed more than 250 tumors with this method. With small
biopsy samples, MLPA often succeeded when FISH failed,
whereas the converse only rarely occurred (Damato B, et al.,
unpublished data, 2009).
Despite including 73 samples, the present study is weak-
ened by the relatively small number of patients. In addition, the
median follow-up of 6.2 years was probably not long enough to
identify all patients destined to die of metastatic disease. Fur-
thermore, several patients died of unrelated causes, possibly
masking metastatic deaths. Another limitation is that postmor-
tem examinations were not performed, so that there is uncer-
tainty about the exact cause of death in some patients. Some
overseas patients were lost to follow-up and may have died of
metastasis. Finally, the survival data may have been influenced,
albeit slightly, by apparently successful resection of liver me-
tastasis in one patient.
It was not a purpose of this study to compare the MLPA
results with those of FISH, which we started performing only
toward the end of the period when these patients were
treated. MLPA confirmed all abnormal FISH results. In addition,
MLPA revealed equivocal abnormalities in chromosomes 3 and
8 and unequivocal gains in chromosome 8 that were not
detected with FISH. We are presently conducting a more in-
depth comparison of MLPA with FISH in a large cohort of
patients treated since 2006. We are also comparing MLPA with
microsatellite analysis (MSA) and will publish the results in
another article. Briefly, MLPA detected equivocal and unequiv-
ocal chromosome 3 abnormalities in 7 and 10 of 32 tumors
showing no loss of heterozygosity (LOH) with MSA. Con-
versely, all 41 tumors with LOH on MSA showed abnormalities
with MLPA (Damato B, et al., unpublished data, 2008).
The results shown in Figure 2B suggest that equivocal losses
in chromosome 3 using MLPA are associated with metastatic
death, whether these involve part or all of the chromosome. It
must be emphasized that only uveal melanoma samples with
good quality MLPA data (i.e., control probes having SD  0.2)
were included for interpretation in this study. If only definite
chromosome 3 losses were considered abnormal (i.e., a DQ of
0.65), then more than 10% of patients with a so-called normal
MLPA result would have died of metastatic disease. Such a high
false-negative rate would be unacceptable in the clinical arena,
essentially preventing any patients from receiving reassurance
about a good prognosis. If even equivocal chromosome 3
losses were considered abnormal (i.e., a DQ between 0.65 and
0.84), then this false-negative rate would be reduced, to the
extent that patients could be confidently reassured of a good
prognosis. Categorization of tumors according to the number
of chromosome 3 loci with equivocal loss resulted, however,
in a high proportion of patients with a 60% 10-year survival
probability. Such an uncertain prognosis is not clinically useful
because, on the one hand, it does not provide reassurance to
FIGURE 2. Kaplan-Meier curves showing rates of metastatic death according to (A) unequivocal (i.e., definite) losses in some or all chromosome
3 loci; (B) equivocal losses in some or all chromosome 3 loci; (C) equivocal and definite losses in chromosome 3; and (D) equivocal or definite
abnormality of any chromosome 3 locus and/or 8q11.23.
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patients and, on the other hand, it does not identify high-risk
patients requiring special care, such as inclusion in any clinical
trials of systemic adjuvant therapy. Categorization of patients
into distinct low-risk, and high-risk groups was improved by
grading tumors according to the presence of equivocal or
definite chromosome 3 losses (Fig. 2C). Prognostication was
also improved by considering chromosome 3 losses together
with 8q gains (Fig. 2D).
The results of this study are consistent with the findings in
our previous studies with regards to chromosome 3 and 8
abnormalities and tumor diameter.11,14 Tumor cell type was
relatively unimportant, however, probably because almost all
lethal uveal melanomas contained epithelioid cells in varying
proportions. As in previous studies, 6p gain correlated with a
good survival prognosis; however, it was excluded as an inde-
pendent predictive factor by multivariate analysis. The detec-
tion of 6p gain is nevertheless useful because its presence
confirms that the specimen contains tumor cells.
The most likely explanation for equivocal MLPA results (i.e.,
a DQ between 0.65 and 0.84) is cellular heterogeneity, with
disomy 3 cells diluting measurements from monosomy 3 cells.
Other studies have demonstrated clonal and genetic heteroge-
neity in uveal melanoma.20–22 The coexistence of 6p gains and
chromosome 3 losses, described to occur in approximately 4%
of uveal melanomas, also merits further investigation.23 The
dilution effect of such cellular heterogeneity makes it neces-
sary for equivocal MLPA results to be interpreted together with
additional tests, such as fluorescence in situ hybridization, so as
to minimize any chances of missing monosomy 3. Because
MLPA provides only relative and not absolute values, FISH is
also useful as a means of distinguishing monosomy 3 from
disomy 3 with hyperploidy. It is likely that the problems
caused by cellular heterogeneity will complicate the interpre-
tation of methods other than MLPA, such as single nucleotide
polymorphism (SNP) arrays.
Our results suggest that there is a possibility of improving
the MLPA kit for uveal melanoma, possibly adding loci on
chromosome 3 as well as on 8p. The criteria for abnormality
also should be revised, to take account of cellular heteroge-
neity. A further limitation of MLPA is that results may be
influenced by abnormalities in genomic loci used as con-
trols. As tumor cells have an unstable genome, additional
positive internal controls may have to be considered in
MLPA investigations.
Further studies are needed to validate the findings of this
investigation, using a new cohort of patients. Such studies
FIGURE 3. MLPA results of four patients, who died of metastatic disease, but who had uveal melanomas with no definite chromosome 3 losses.
(A) Gains in chromosome 3p (VHL and MLH1) loci and low normal chromosome 3p and 3q (SEMA3B and RHO) values. (B) Equivocal losses of all
3q loci. (C,D) Equivocal losses on the long and short arms of chromosome 3. The DNA of (D) was of inferior quality as shown by the control values.
Nevertheless, this tumor was unusual in that it showed gains in 6p together with partial and equivocal deletions of 3p. Dotted lines: separate normal
from equivocal abnormality; dashed lines: demarcate equivocal from definite abnormality.
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would enable estimation of sensitivity and specificity of MLPA
in predicting metastatic death, as well as positive and negative
predictive values. It is also necessary to investigate specifically
the predictive value of MLPA when performed on tiny tumor
specimens, obtained by fine needle aspiration biopsy or with a
vitreous cutter. This is because in mosaic tumors, such tumor
sampling may miss the most aggressive parts of the tumor.
MLPA and other methods of genomic tumor typing only
determine whether the uveal melanoma has any metastatic
potential. If the tumor is indeed lethal, then to estimate the
likely survival time, it is necessary to take account of (1) clinical
tumor stage, which indicates how long any metastases are
likely to have been growing (i.e., lead-time bias); and (2)
histologic grade, which reflects the rate of growth of such
metastases (i.e., tumor doubling time).
In conclusion, MLPA is useful for estimating the probability
of metastatic death after treatment of uveal melanoma, but
requires multivariate analysis of chromosomes 3 and 8, also
taking into account the clinical stage and histologic grade of
tumor malignancy.
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